Sudden cardiac death: Opportunities for prevention

Heart

Volumn 92, Issue 6, 2006, Pages 721-723

  Morgan, John M ^a,b   Cowan, J C ^c   Camm, A J ^d   McComb, J M ^e  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b Wessex Cardiology   (United Kingdom)

^c The Yorkshire Heart Center   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; EVIDENCE BASED MEDICINE; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; UNITED KINGDOM;

EID: 33744501504     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Department of Health. Chapter 8. Arrhythmias and sudden cardiac death. In, National service framework for coronary heart disease. London, Department of Health, 2005.
2. National Institute for Clinical Excellence. Technology Appraisal Guidance No 11 Guidance on the use of implantable cardioverter defibrillators for arrhythmias. London: NICE, September, 2000.
3. National Institute for Health and Clinical Excellence. Appraisal Consultation Document: implantable cardioverter defibrillators for arrhythmias (review of existing guidance no. 11). London: NICE, 2005.
4. Cunningham A, Cunningham M, Rickards AF. National pacemaker database. National ICD database, 2002.
5. Moss A, Zareba W, Hall W, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
6. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
7. Gregatoros G, Abrams J, Epstein A, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association/task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemaker guidelines). Circulation 2002;106:2145-61.
8. Tang AS, Ross H, Simpson C, et al. Position paper on implantable cardioverter defibrillator (ICD) use in Canada. Can J Cardiol 2005;21:11A-18A.
9. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003;24:13-15.
10. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). The task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
11. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for malignant ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med 1996;335:1933-40.
12. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden cardiac death in patients with coronary artery disease. N Engl J Med 1999;341:1882-90.
13. Cappato R, Boczor S, Kuck KH, et al. Response to programmed ventricular stimulation and clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter defibrillator or antiarrhythmic drug therapy. Eur Heart J 2004;25:642-9.
14. Brodsky MA, Mitchell LB, Halperin BD, et al. Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhthymia: the antiarrhythmics versus implantable defibrillators (AVID) trial. Am Heart J 2002;144:478-84.
15. Buxton A, Moss AJ. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter defibrillator? Circulation 2005;111:2537-49.
16. Domanski MJ, Saksena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 1999;34:1090-5.
17. Sheldon R, Connolly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter defibrillator thearpy. The Canadian implantable defibrillator study. Circulation 2000;101:1660-4.
18. Burke JL, Hallas CN, Clark-Carter D, et al. The psychological impact of the implantable cardioverter defibrillator: a meta analytic review. Br J Health Psychol 2003;8:165-78.
19. The DAVID Trial Investigators. Dual chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. The dual chamber and WI implantable defibrillator (DAVID) trial. JAMA 2002;288:3115-23.
20. Salukhe TV, Dimopoulos K, Sutton R, et al. Life years gained from defibrillator implantation markedly nonlinear increase during 3 years of follow up and its implications. Circulation 2004;109:1848-53.
21. Bokhari F, Newman D, Greene M, et al. Long term comparison of the implantable cardioverter defibrillator versus amiodarone. Eleven year follow up of a subset of patients in the Canadian implantable defibrillator study (CIDS). Circulation 2004;110:112-16.
22. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic implications of the multicenter automatic defibrillator implantation trial-II. Ann Intern Med 2005;142:593-600.
23. Sheldon R, O'Brien BJ, Blockhouse G, et al. Effect of clinical risk stratification on cost effectiveness of the implantable cardioverter. The Canadian implantable defibrillator study. Circulation 2001;104:1622-6.